posted on 2021-09-02, 19:15authored byWilliam S. Gange, Khristina Lung, Jennifer Lopez, Benjamin Y. Xu, Seth A. Seabury, Brian C. Toy
<b>Objective:</b> To determine the incidence and risk
factors for developing proliferative diabetic retinopathy (PDR), tractional
retinal detachment (TRD), and neovascular glaucoma (NVG) at 5 years after
initial diagnosis of type 2 diabetes.
<p><b>Research Design and
Methods: </b>Insured
patients age 18 or older with newly-diagnosed type 2 diabetes and 5 years of
continuous enrollment were identified from a nationwide commercial claims
database containing data from 2007-2015.<b>
</b>The<b> </b>incidences of PDR, TRD, and NVG were computed at 5 years following
index diagnosis of type 2 diabetes.<b> </b>Associations
between these outcomes and demographic, socioeconomic, and medical factors were
tested with multivariable logistic regression.</p>
<p><b>Results:</b> At 5 years following initial diagnosis
of type 2 diabetes, 1.74% (1,249/71,817) of patients had developed PDR.
Additionally, 0.25% of patients had developed TRD, and 0.14% of patients had
developed NVG. Insulin use (OR 3.59, 95% CI 3.16-4.08), maximum HbA1c >9% or
75mmol/mol
(OR 2.10, 95% CI 1.54-2.69), renal disease (OR 2.68, 95% CI 2.09-3.42),
peripheral circulatory disorders (OR 1.88, 95% CI 1.25-2.83), neurological
disease (OR 1.62, 95% CI 1.24-2.11), and older age at diagnosis (age 65-74, OR
1.62, 1.28-2.03) were identified as risk factors for development of PDR at 5
years. Young age at diagnosis (age 18-34, OR 0.46, 95% CI 0.29-0.74), Medicare
insurance (OR 0.60, 95% CI 0.70-0.76), morbid obesity (OR 0.72, 95% CI
0.59-0.87), and smoking (OR 0.84, 95% CI 0.70-1.00) were identified as
protective factors. </p>
<p><b>Conclusions:</b> A subset of patients with type 2
diabetes develop PDR and other neovascular sequelae within the first 5 years
following diagnosis with type 2 diabetes. These patients may benefit from
increased efforts for screening and early intervention.</p>
Funding
This study was supported by NIH Grant P30EY029220 and an unrestricted departmental award from Research to Prevent Blindness, New York, NY. The sponsor or funding organizations had no role in the design or conduct of this research.